Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine-University, Bergische Landstraße 2, 40629 Düsseldorf, Germany.
Int J Mol Sci. 2024 Feb 11;25(4):2188. doi: 10.3390/ijms25042188.
Antipsychotic drug (APD) medication can lead to metabolic dysfunctions and weight gain, which together increase morbidity and mortality. Metabolically active visceral adipose tissue (VAT) in particular plays a crucial role in the etiopathology of these metabolic dysregulations. Here, we studied the effect of 12 weeks of drug medication by daily oral feeding of clozapine and haloperidol on the perirenal fat tissue as part of VAT of male and female Sprague Dawley rats in the context of complex former investigations on brain, liver, and blood. Adipocyte area values were determined, as well as triglycerides, non-esterified fatty acids (NEFAs), glucose, glycogen, lactate, malondialdehyde equivalents, ferric iron and protein levels of Perilipin-A, hormone-sensitive-lipase (HSL), hepcidin, glucose transporter-4 (Glut-4) and insulin receptor-ß (IR-ß). We found increased adipocyte mass in males, with slightly higher adipocyte area values in both males and females under clozapine treatment. Triglycerides, NEFAs, glucose and oxidative stress in the medicated groups were unchanged or slightly decreased. In contrast to controls and haloperidol-medicated rats, perirenal adipocyte mass and serum leptin levels were not correlated under clozapine. Protein expressions of perilipin-A, Glut-4 and HSL were decreased under clozapine treatment. IR-ß expression changed sex-specifically in the clozapine-medicated groups associated with higher hepcidin levels in the perirenal adipose tissue of clozapine-treated females. Taken together, clozapine and haloperidol had a smaller effect than expected on perirenal adipose tissue. The perirenal adipose tissue shows only weak changes in lipid and glucose metabolism. The main changes can be seen in the proteins examined, and probably in their effect on liver metabolism.
抗精神病药物(APD)治疗会导致代谢功能紊乱和体重增加,从而增加发病率和死亡率。代谢活跃的内脏脂肪组织(VAT)在这些代谢失调的发病机制中起着至关重要的作用。在这里,我们研究了通过每日口服氯氮平和氟哌啶醇给药 12 周对雄性和雌性 Sprague Dawley 大鼠肾周脂肪组织(作为 VAT 的一部分)的影响,这是对大脑、肝脏和血液进行的复杂先前研究的一部分。确定了脂肪细胞面积值,以及甘油三酯、非酯化脂肪酸(NEFAs)、葡萄糖、糖原、乳酸、丙二醛当量、三价铁和脂肪酶相关蛋白( perilipin-A)、激素敏感脂肪酶(HSL)、hepcidin、葡萄糖转运蛋白-4(Glut-4)和胰岛素受体-β(IR-ß)的蛋白水平。我们发现雄性大鼠的脂肪细胞质量增加,氯氮平治疗组的雄性和雌性大鼠的脂肪细胞面积值略高。药物治疗组的甘油三酯、NEFAs、葡萄糖和氧化应激没有变化或略有下降。与对照组和氟哌啶醇治疗组的大鼠不同,氯氮平治疗组肾周脂肪细胞质量和血清瘦素水平没有相关性。氯氮平治疗组 perilipin-A、Glut-4 和 HSL 的蛋白表达减少。氯氮平治疗组的 IR-ß 表达发生了性别特异性变化,与氯氮平治疗雌性大鼠肾周脂肪组织中较高的 hepcidin 水平相关。总的来说,氯氮平和氟哌啶醇对肾周脂肪组织的影响比预期的要小。肾周脂肪组织在脂质和葡萄糖代谢方面仅显示出微弱的变化。主要变化可以在检查的蛋白质中看到,并且可能在其对肝脏代谢的影响中看到。